{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:24:26Z","timestamp":1791343466459,"version":"4.3.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Marginal zone lymphomas are indolent B-cell lymphomas that originate from the marginal zone of B-cell follicles. For several subtypes, the initiation of disease appears to be a consequence of chronic infection and\/ or inflammation. While the initial lymphoid hyperplasia is driven by physiologic antigenic stimulation, additional oncogenic events, such as chromosomal translocations leading to constitutive activation of signaling pathways, occur during the progression of disease that ultimately result in antigen-independent lymphoproliferation. Despite having a common origin in the marginal zone of the B-cell follicle, there are distinct clinical and molecular characteristics of marginal zone lymphomas originating at different anatomic sites. As such, marginal zone\u2013derived lymphomas are currently categorized by the World Health Organization (WHO) into those originating in the spleen (splenic marginal zone lymphoma), extranodal mucosa-associated lymphoid tissue (MALT lymphoma), or lymph node (nodal marginal zone lymphoma).<\/jats:p>","DOI":"10.1182\/asheducation-2008.1.359","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T10:12:58Z","timestamp":1228990378000},"page":"359-364","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL"],"prefix":"10.1182","volume":"2008","author":[{"given":"Brad","family":"Kahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111711045500000_R1","doi-asserted-by":"crossref","unstructured":"Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034\u20133044.","DOI":"10.1182\/blood-2005-09-3679"},{"key":"2019111711045500000_R2","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood. 1997;89:3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"2019111711045500000_R3","doi-asserted-by":"crossref","unstructured":"Campo E, Miquel R, Krenacs L, Sorbara L, Raffeld M, Jaffe ES. Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol. 1999;23:59\u201368.","DOI":"10.1097\/00000478-199901000-00006"},{"key":"2019111711045500000_R4","doi-asserted-by":"crossref","unstructured":"Kost CB, Holden JT, Mann KP. Marginal zone B-cell lymphoma: a retrospective immunophenotypic analysis. Cytometry B Clin Cytom. 2008;74:282\u2013286.","DOI":"10.1002\/cyto.b.20426"},{"key":"2019111711045500000_R5","doi-asserted-by":"crossref","unstructured":"Conconi A, Bertoni F, Pedrinis E, et al. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood. 2001;98:781\u2013786.","DOI":"10.1182\/blood.V98.3.781"},{"key":"2019111711045500000_R6","doi-asserted-by":"crossref","unstructured":"Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol. 2000;156:1183\u20131188.","DOI":"10.1016\/S0002-9440(10)64988-7"},{"key":"2019111711045500000_R7","doi-asserted-by":"crossref","unstructured":"Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood. 1996;87:299\u2013307.","DOI":"10.1182\/blood.V87.1.299.299"},{"key":"2019111711045500000_R8","doi-asserted-by":"crossref","unstructured":"Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950\u20131956.","DOI":"10.1182\/blood.V95.6.1950"},{"key":"2019111711045500000_R9","doi-asserted-by":"crossref","unstructured":"Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin\u2019s Lymphoma Classification Project. J Clin Oncol. 1999;17:2486\u20132492.","DOI":"10.1200\/JCO.1999.17.8.2486"},{"key":"2019111711045500000_R10","doi-asserted-by":"crossref","unstructured":"Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of fludarabine and rituximab for the treatment of marginal zone lymphomas [abstract]. Blood.2007;110. Abstract#1358.","DOI":"10.1182\/blood.V110.11.1358.1358"},{"key":"2019111711045500000_R11","doi-asserted-by":"crossref","unstructured":"Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 2002;99:1299\u20131304.","DOI":"10.1182\/blood.V99.4.1299"},{"key":"2019111711045500000_R12","doi-asserted-by":"crossref","unstructured":"Bahler DW, Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas appear to originate from different B cell types. Am J Pathol. 2002;161:81\u201388.","DOI":"10.1016\/S0002-9440(10)64159-4"},{"key":"2019111711045500000_R13","doi-asserted-by":"crossref","unstructured":"Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005;106:1831\u20131838.","DOI":"10.1182\/blood-2004-10-3898"},{"key":"2019111711045500000_R14","doi-asserted-by":"crossref","unstructured":"Hernandez JM, Garcia JL, Gutierrez NC, et al. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol. 2001;158:1843\u20131850.","DOI":"10.1016\/S0002-9440(10)64140-5"},{"key":"2019111711045500000_R15","doi-asserted-by":"crossref","unstructured":"Callet-Bauchu E, Baseggio L, Felman P, et al. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia. 2005;19:1818\u20131823.","DOI":"10.1038\/sj.leu.2403909"},{"key":"2019111711045500000_R16","doi-asserted-by":"crossref","unstructured":"Satoh T, Yamada T, Nakano S, et al. The relationship between primary splenic malignant lymphoma and chronic liver disease associated with hepatitis C virus infection. Cancer. 1997;80:1981\u20131988.","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1981::AID-CNCR16>3.0.CO;2-U"},{"key":"2019111711045500000_R17","doi-asserted-by":"crossref","unstructured":"Arcaini L, Burcheri S, Rossi A, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007;18:346\u2013350.","DOI":"10.1093\/annonc\/mdl388"},{"key":"2019111711045500000_R18","doi-asserted-by":"crossref","unstructured":"Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89\u201394.","DOI":"10.1056\/NEJMoa013376"},{"key":"2019111711045500000_R19","doi-asserted-by":"crossref","unstructured":"Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107:4643\u20134649.","DOI":"10.1182\/blood-2005-11-4659"},{"key":"2019111711045500000_R20","doi-asserted-by":"crossref","unstructured":"Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002;3:41\u201347.","DOI":"10.3816\/CLM.2002.n.010"},{"key":"2019111711045500000_R21","doi-asserted-by":"crossref","unstructured":"El Weshi A, Ribrag V, Girinski T, El Hajj M, Dhermain F, Bayle C. Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes. Br J Haematol. 1998;103:1212\u20131213.","DOI":"10.1046\/j.1365-2141.1998.1161f.x"},{"key":"2019111711045500000_R22","doi-asserted-by":"crossref","unstructured":"Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003;101:2464\u20132472.","DOI":"10.1182\/blood-2002-07-2216"},{"key":"2019111711045500000_R23","unstructured":"Kalpadakis C, Pangalis G, Vassilakopoulos T, et al. Rituximab monotherapy is the treatment of choice of splenic marginal zone lymphoma (SMZL) [abstract]. Ann Oncol.2008;19. Abstract #367."},{"key":"2019111711045500000_R24","doi-asserted-by":"crossref","unstructured":"Raderer M, Wohrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol. 2006;24:3136\u20133141.","DOI":"10.1200\/JCO.2006.06.0723"},{"key":"2019111711045500000_R25","doi-asserted-by":"crossref","unstructured":"Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET\/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007;79:205\u2013209.","DOI":"10.1111\/j.1600-0609.2007.00895.x"},{"key":"2019111711045500000_R26","doi-asserted-by":"crossref","unstructured":"Kahl BS. Update: gastric MALT lymphoma. Curr Opin Oncol. 2003;15:347\u2013352.","DOI":"10.1097\/00001622-200309000-00001"},{"key":"2019111711045500000_R27","doi-asserted-by":"crossref","unstructured":"Lucas PC, Kuffa P, Gu S, et al. A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment. Oncogene. 2007;26:5643\u20135654.","DOI":"10.1038\/sj.onc.1210342"},{"key":"2019111711045500000_R28","doi-asserted-by":"crossref","unstructured":"Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002;122:1286\u20131294.","DOI":"10.1053\/gast.2002.33047"},{"key":"2019111711045500000_R29","doi-asserted-by":"crossref","unstructured":"Ye H, Gong L, Liu H, et al. Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication. Gut. 2006;55:137\u2013138.","DOI":"10.1136\/gut.2005.081117"},{"key":"2019111711045500000_R30","doi-asserted-by":"crossref","unstructured":"Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998;16:1916\u20131921.","DOI":"10.1200\/JCO.1998.16.5.1916"},{"key":"2019111711045500000_R31","doi-asserted-by":"crossref","unstructured":"Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BM. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol. 2008;87:405\u2013411.","DOI":"10.1016\/j.radonc.2008.02.012"},{"key":"2019111711045500000_R32","doi-asserted-by":"crossref","unstructured":"Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02\/96). J Clin Oncol. 2005;23:7050\u20137059.","DOI":"10.1200\/JCO.2005.04.031"},{"key":"2019111711045500000_R33","doi-asserted-by":"crossref","unstructured":"Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin\u2019s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23:1979\u20131983.","DOI":"10.1200\/JCO.2005.08.128"},{"key":"2019111711045500000_R34","doi-asserted-by":"crossref","unstructured":"Morgner A, Schmelz R, Thiede C, Stolte M, Miehlke S. Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol. 2007;13:3554\u20133566.","DOI":"10.3748\/wjg.v13.i26.3554"},{"key":"2019111711045500000_R35","doi-asserted-by":"crossref","unstructured":"Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005;23:5061\u20135066.","DOI":"10.1200\/JCO.2005.05.660"},{"key":"2019111711045500000_R36","doi-asserted-by":"crossref","unstructured":"Zucca E, Dreyling M. Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol.2008;19 Suppl 2:ii70\u201371.","DOI":"10.1093\/annonc\/mdn094"},{"key":"2019111711045500000_R37","doi-asserted-by":"crossref","unstructured":"Noy A, Yahalom J, Zaretsky L, Brett I, Zelenetz AD. Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy. J Clin Oncol. 2005;23:3768\u20133772.","DOI":"10.1200\/JCO.2005.10.018"},{"key":"2019111711045500000_R38","doi-asserted-by":"crossref","unstructured":"Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005;23:8018\u20138024.","DOI":"10.1200\/JCO.2005.02.3903"},{"key":"2019111711045500000_R39","doi-asserted-by":"crossref","unstructured":"Guidoboni M, Ferreri AJ, Ponzoni M, Doglioni C, Dolcetti R. Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives. Clin Lymphoma Myeloma. 2006;6:289\u2013300.","DOI":"10.3816\/CLM.2006.n.003"},{"key":"2019111711045500000_R40","doi-asserted-by":"crossref","unstructured":"Thieblemont C, de la Fouchardiere A, Coiffier B. Nongastric mucosa-associated lymphoid tissue lymphomas. Clin Lymphoma. 2003;3:212\u2013224.","DOI":"10.3816\/CLM.2003.n.002"},{"key":"2019111711045500000_R41","doi-asserted-by":"crossref","unstructured":"Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489\u20132495.","DOI":"10.1182\/blood-2002-04-1279"},{"key":"2019111711045500000_R42","unstructured":"Goda J, Gospodarowicz MK, Pintilie M, et al. Long-term outcome following radiotherapy in localized extranodal MALT lymphomas [abstract]. Ann Oncol.2008;19. Abstract #062."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/359\/786408\/359_364ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/359\/786408\/359_364ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T11:05:11Z","timestamp":1573988711000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2008\/1\/359\/95792\/Marginal-Zone-Lymphomas-Management-of-Nodal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2008.1.359","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}